Spectrum Pharm (SPPI) July volatility at 234, August at 170 into PDUFA
Up)
Spectrum (Nasdaq: SPPI) : Spectrum Pharm is recently down 36c to $7.29. SPPI's Zevalin, a first line consolidation therapy for non-Hodgkin's Lymphoma, has a PDUFA on July 2. SPPI July 7.5 straddle is priced at $2.80, August is at $3.15. SPPI July option implied volatility is at 234, August is at 170; above its six month average of 100, according to Track Data, suggesting large price risk. Paul Foster
You May Also Be Interested In
- Morgan Stanley (MS) Shares Pressured on Questionable Facebook (FB) Tactics; Hits Fresh 6-Month Low
- Arena Pharma (ARNA) Volatility Elevated, Shares Higher After Close of $70M Offering
- Hewlett-Packard (HPQ) May weekly call volatility elevated at 84 into Q2
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
